Uncategorized
Roclatan demonstrates positive safety results at 12 months in phase 3 trial
Aerie Pharmaceuticals released successful 12-month safety results for the Mercury 1 phase 3 registration trial for Roclatan, a once-daily eye drop to lower IOP. The 12-month safety and efficacy trial, which included a 90-day efficacy endpoint, showed consistent safety results for Roclatan, a combination of Rhopressa (netarsudil ophthalmic solution 0.02%) and latanoprost, with no new adverse events after the initial 90-day efficacy period of the trial, according to a company press release.